Gaurav Singh, MD, MPH, explains how pharmacokinetics, trial design, and real-world tolerability set sonidegib apart from vismodegib in locally advanced basal cell carcinoma and when to start systemic therapy earlier.
|Articles|March 1, 2023
Pointers With Portela: What to Know About Mohs Surgery
Author(s)Dustin Portela, DO
In this week’s Pointers with Dr Portela, the 208SkinDoc discusses basal cell carcinoma and Mohs surgery related to Jill Biden's most recent skin cancer diagnosis.
Advertisement
Dustin Portela, DO, a board-certified dermatologist and dermatologic surgeon at Treasure Valley Dermatology in Boise, Idaho, reviews the recent news of Jill Biden's basal cell carcinoma diagnosis. Portela explains how Mohs surgery is used to treat skin cancer lesions, and how the procedure damages as little tissue as possible.
Opinions expressed are that of Portela and do not express the views or opinions of Dermatology Times®.
Advertisement
Related to this article
Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
Phase 3 data show intismeran plus pembrolizumab reduced recurrence or death risk by 42% in patients with resected stage IIB-IV melanoma.
Cosibelimab-ipdl is now an NCCN Category 2A option for locally advanced CSCC in patients ineligible for curative surgery or radiation.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
The AADA warns that dermatologists could face a 6% Medicare payment reduction in 2027 despite CMS revisions to modifier 25 policies.
Pediatric dermatologists outline how to evaluate suspected topical steroid withdrawal, exclude mimics, and preserve family trust in eczema care.
Diego Ruiz Dasilva, MD, and Lindsey Finklea, MD, discuss the burden of chronic inducible urticaria and phase 3 remIND findings for remibrutinib.
Advertisement
Advertisement
Trending on Dermatology Times
1
AADA Warns of 6% Medicare Payment Cut for Dermatologists in 2027
2
Don't Be Rash: Navigating Topical Steroid Withdrawal Concerns in Pediatric Eczema
3
Systemic Therapy Selection in Pediatric and Adult Atopic Dermatitis
4
Women’s Health Needs in Psoriasis and Atopic Dermatitis
5